Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt

Melanoma (Skin): early-phase trial registry

7 of 54 indexed Melanoma (Skin) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #261 of 28,707 conditions by registered trial count.

54 US clinical trials · 7 currently recruiting · #261 of 28,707 conditions by registered trial count

Melanoma (Skin): 54 US clinical trials tracked, 7 recruiting.

Melanoma (Skin) is the subject of 54 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.

Enrollment posture brief

Registry condition melanoma-skin

OPEN 7 | RECR 13% | LATE 1 | EARLY 49 | RANK #261 | SPON 10

Nearest open-share peer: Myocardial Ischemia (13% recruiting · 31 trials)

Cirrhosis53.7%Colorectal Carcinoma51.9%Obesity, Childhood46.3%Melanoma (this)13%Brain and Central Nervous Sy1.8%
Open-enrollment share among volume-matched conditions near Melanoma (Skin)

Melanoma (Skin) lists 7 open slots (13% of 54 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Melanoma (Skin) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Melanoma (Skin) is recruiting below its size-band peers.

    7 of 54 indexed trials (13%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Melanoma (Skin) research.

    National Cancer Institute (NCI) accounts for 10 of 54 trials (18.5%). 33 distinct sponsors appear on at least one study for this condition label.

  3. Most Melanoma (Skin) trials plan to enrol fewer than 100 people.

    Median target enrolment is 35 among the 31 trials that report a genuine target (sentinel values excluded). 23 of those (74.2%) plan for fewer than 100 participants.

  4. Melanoma (Skin) research is mostly interventional.

    53 interventional and 1 observational studies make up this index (98.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 127Phase 222Phase 31

Phase Distribution

PhaseTrial count
Phase 1 27
Phase 2 22
Phase 3 1

Named interventions

Most-linked intervention names on Melanoma (Skin) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

aldesleukin Biological
13 trials
incomplete Freund's adjuvant Biological
11 trials
gp100 antigen Biological
9 trials
MART-1 antigen Biological
5 trials
sargramostim Biological
4 trials
tyrosinase peptide Biological
3 trials
therapeutic tumor infiltrating lymphocytes Biological
3 trials
cyclophosphamide Drug
3 trials

US sites by state

Facility locations filed on Melanoma (Skin) trials. A trial with sites in several states counts in each.

Maryland 13 trials
New York 8 trials
California 7 trials
Illinois 6 trials
Texas 5 trials
Florida 5 trials
Arizona 5 trials
Washington 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Melanoma (Skin) page

54 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma (Skin) condition card totals 54 registered trials; most-linked intervention aldesleukin; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.